Moleculin Biotech, Inc.
MBRXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 28, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Dec 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Sep 10, 2025 |
| HC Wainwright & Co. | maintain | Buy | Aug 27, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jun 18, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 25, 2025 |
| Maxim Group | upgrade | Hold →Buy | Mar 25, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 3, 2025 |
| Maxim Group | maintain | Buy | Nov 12, 2024 |
| Roth MKM | maintain | Buy | Apr 12, 2024 |
| Maxim Group | maintain | Buy | Mar 26, 2024 |
| Roth MKM | maintain | Buy | Apr 18, 2023 |
| Oppenheimer | maintain | Outperform | Mar 24, 2023 |
| Oppenheimer | maintain | Outperform | Oct 17, 2019 |
| Maxim Group | maintain | Buy | Nov 14, 2018 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-8.87| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-28.00 | $-31.00 | — | — |
| May 12, 2026 | $-3.54 | $-33.80 | — | — |
| Mar 20, 2026 | $-57.00 | $-122.27 | — | — |
| Nov 14, 2025 | $-17.02 | $-4.00 | — | — |
| Aug 12, 2025 | $-12.25 | $-9.75 | — | — |
| May 14, 2025 | $-13.80 | $-14.20 | — | — |
| Mar 24, 2025 | $-25.80 | $-30.80 | — | — |
| Nov 11, 2024 | $-57.00 | $-48.80 | — | — |
News
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML
Milestone underscores execution of pivotal Phase 2/3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory acute myeloid leukemia (AML)
Access the Moleculin CEO Corner here
HOUSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-20 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on October 20, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market…
HOUSTON, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it will present at the upcoming 2026 Maxim Growth Summit in New York, NY. Details of the presentation are as follows:
HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that it has completed and closed enrollment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML), with 89 subjects enrolled and an additional subject currently in screening. With Part A enrollment closed, the Company remain…
– Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits
Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin's antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its direct cytotoxic activity
Strengthens Global Intellectual Property Estate for Annamycin's Proprietary Liposomal Formulation Designed to Target Lung Metastases While Supporting Long-Term Commercial Opportunity
Presentations examine where Annamycin concentrates in the body, how it targets topoisomerase II, and its antitumor activity in pancreatic cancer
HOUSTON, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that its pre-recorded presentation from the H.C. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.
Moleculin Biotech, Inc. (NASDAQ: MBRX - Get Free Report) shares crossed below its 50 day moving average during trading on Thursday. The stock has a 50 day moving average of $1.21 and traded as low as $0.7735. Moleculin Biotech shares last traded at $0.8299, with a volume of 531,906 shares trading hands. Analysts Set New
- Video webcast now available here
Moleculin Biotech (MBRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive interim MIRACLE data showed complete remission rates three times higher than control in relapsed/refractory AML MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe MIRACLE trial Part B initiation expected in the first half of 2027 following optimal dose selection Cash position, including $9.3 million raised after quarter-end, expected to fund operations into the first qua…